New Medication Lowers Refractory Hypertension in CKD
- A new medication, developed by Travere therapeutics, has demonstrated a statistically notable and clinically meaningful reduction in blood pressure among individuals with chronic kidney disease (CKD) and arduous-to-control...
- Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA).
- The SPARTA study specifically focused on patients with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder.
“`html
New Medication Significantly Lowers Blood Pressure in Chronic Kidney Disease patients
Table of Contents
Published September 7, 2025, at 22:12:51 (Updated as needed)
what Happened?
A new medication, developed by Travere therapeutics, has demonstrated a statistically notable and clinically meaningful reduction in blood pressure among individuals with chronic kidney disease (CKD) and arduous-to-control hypertension.The findings, announced on september 7, 2025, are based on data from the pivotal Phase 3 clinical trial, SPARTA study. The medication,sparsentan,targets both the angiotensin II and endothelin-1 pathways.
Understanding Sparsentan and its Mechanism
Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA). Customary treatments for hypertension often focus on single pathways. Sparsentan’s unique mechanism of action, concurrently blocking both endothelin-1 and angiotensin II receptors, offers a novel approach to blood pressure management in CKD. Research published in Hypertension details the role of these pathways in CKD-related hypertension.
The SPARTA study specifically focused on patients with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder. Tho, the broader implications for hypertension management in all CKD stages are significant.
SPARTA Study Results: Key Data
The Phase 3 SPARTA study involved 335 participants with FSGS and persistent proteinuria despite standard therapies. The primary endpoint was the change in urine protein-to-creatinine ratio (UPCR) from baseline to 18 months. Secondary endpoints included changes in estimated glomerular filtration rate (eGFR) and blood pressure.
| Endpoint | Sparsentan Group | Placebo Group | p-value |
|---|---|---|---|
| Change in UPCR from Baseline | -45.2% | -13.3% | <0.0001 |
| Change in Systolic Blood pressure (SBP) from baseline (mmHg) | -13.2 mmHg | -3.1 mmHg | <0.0001 |
| Change in Diastolic Blood Pressure (DBP) from Baseline (mmHg) | -7.1 mmHg | -1.5 mmHg | <0.0001 |
Who is Affected?
approximately 37 million adults in the United States have chronic kidney disease. Hypertension is both a cause and a consequence of CKD, creating a challenging cycle for patients and clinicians. Traditional blood pressure medications may be less effective in CKD patients, and can sometimes worsen kidney function. This new medication offers a potential solution for those who haven’t responded adequately to existing treatments.
The initial focus is on FSGS patients, but the potential